title: Examination of the rescue effects of folic acid on derangement of the tubo-ovarian ultrastructural architecture caused by methotrexate.
abstract: The purpose of this examination was to observe the effects of folic acid (FA) on methotrexate (MTX)-induced derangements in the fallopian tubes. Investigators in this study sought to explore whether MTX-induced dysfunction in the fallopian tubes would be lessened by the addition of FA to MTX treatment. For this study, 18 albino Wistar rats were randomly divided into 6 groups, each of which comprised 3 rats; 0.1 mg/kg FA, 1 mg/kg MTX + 0.1 mg/kg FA, 5 mg/kg MTX + 0.1 mg/kg FA, 1 mg/kg MTX, and 5 mg/kg MTX were given to groups 2, 3, 4, 5,and 6, respectively; group 1 was the control group. After MTX injection, fallop-ian tube samples from all groups were prepared for examination under electron microscopy. The findings observed in groups 1 and 2 were similar. The level of cellular destruction was greater with the higher doses of MTX without FA; in particular, loss of cilia in the epithelium was prominent in groups 5 and 6. However, there was less cellular destruction observed in groups 3 and 4 than in groups 5 and 6. As a result, the addition of FA should not be overlooked, even when a single-dose MTX regimen is chosen for the treatment of patients with unruptured ectopic pregnancy.
authors.affiliation: Department of Obstetrics and Gynecology, Gazi University, Ankara, Turkey.
authors.forename: Merih
authors.initials: M
authors.lastname: Bayram
authors.forename: Candan
authors.initials: C
authors.lastname: Ozogul
authors.forename: Z Sevim
authors.initials: ZS
authors.lastname: Ercan
authors.forename: Ergin
authors.initials: E
authors.lastname: Dilekoz
authors.forename: Canan
authors.initials: C
authors.lastname: Soyer
authors.forename: Orhan
authors.initials: O
authors.lastname: Bayram
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005187:Fallopian Tubes / Q000187:drug effects* / Q000648:ultrastructure; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D008727:Methotrexate / Q000009:adverse effects*; D008854:Microscopy, Electron; D046529:Microscopy, Electron, Transmission; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014803:Vitamin B Complex / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D014803:Vitamin B Complex; D005492:Folic Acid; D008727:Methotrexate